|1.||Gudkov, Andrei V: 5 articles (01/2014 - 04/2008)|
|2.||Burdelya, Lyudmila G: 4 articles (01/2014 - 04/2008)|
|3.||Aygun-Sunar, Semra: 3 articles (01/2014 - 05/2012)|
|4.||Leigh, Nicholas D: 2 articles (01/2014 - 11/2012)|
|5.||Liu, Hong: 2 articles (01/2014 - 11/2012)|
|6.||Bian, Guanglin: 2 articles (01/2014 - 11/2012)|
|7.||Cao, Xuefang: 2 articles (01/2014 - 11/2012)|
|8.||Ding, Xilai: 2 articles (01/2014 - 11/2012)|
|9.||Krivokrysenko, Vadim I: 2 articles (05/2012 - 04/2008)|
|10.||Feinstein, Elena: 2 articles (05/2012 - 04/2008)|
11/15/2012 - "Using two tumor models that do not express TLR5, and thereby do not directly respond to CBLB502, we found that CBLB502 treatment significantly enhanced allogeneic CD8(+) T cell-mediated GVT activity, which was evidenced by decreased tumor burden and improved host survival. "
05/01/2012 - "CBLB502 combines properties of supportive care (radiotherapy adjuvant) and anticancer agent, both mediated via activation of TLR5 signaling in the normal tissues or the tumor, respectively."
01/01/2014 - "Upon challenge with the T-cell lymphoma RMAS, CBLB502 treatment after tumor inoculation protects C57BL/6 mice from death caused by tumor growth. "
01/01/2014 - "We examined the effect of CBLB502 on tumor immunity using two syngeneic lymphoma models, both of which do not express TLR5, and thus do not directly respond to CBLB502. "
11/15/2012 - "Moreover, mechanistic analyses showed that CBLB502 stimulates CD8(+) T cell proliferation and enhances their tumor killing activity mainly indirectly through a mechanism that involves the IL-12 signaling pathway and the CD11c(+) and CD11b(+) populations in the bone marrow cells. "
05/01/2012 - "CBLB502 significantly reduced the severity of dermatitis and mucositis, accelerated tissue recovery, and reduced the extent of radiation induced weight loss in mice after a single dose of 15 or 20 Gy but not 25 Gy of radiation. "
01/01/2016 - "It has been reported that CBLB502, a novel agonist of TLR5 derived from Salmonella flagellin, could reduce radiation toxicity in mouse and primate models, protect mice from dermatitis and oral mucositis caused by radiation, inhibit acute renal ischemic failure, and inhibit the growth of A549 lung cancer cell. "
|3.||Acute Radiation Syndrome
|5.||B-Cell Lymphoma (Lymphoma, B Cell)
|1.||Toll-Like Receptor 5
|3.||Interleukin-12 (IL 12)
|4.||Adenocarcinoma of lung
|1.||Heterologous Transplantation (Xenotransplantation)